← Human Trials & Peer-Reviewed Studies
Influence of High-Intensity Interval Training on IGF-1 Response, Brain Executive Function, Physical Fitness and Quality of Life in Sedentary Young University Women-Protocol for a Randomized Controlled Trial
Plain-language guide to PMID 37047943 (2023): randomized and parallel-group clinical study of IGF-1 LR3 in 77 women.
Key Facts
- PMID
- 37047943
- Journal
- International journal of environmental research and public health
- Year
- 2023
- Study type
- Clinical Study
- Authors
- Jiménez-Roldán MJ et al. (3 authors)
- DOI
- 10.3390/ijerph20075327
What This Study Did, in Plain Language
What Was Tested
Researchers studied IGF-1 LR3 in this clinical study publication.
Sedentary lifestyles have become a social problem, mainly among women.
At least 77 women will be recruited and randomly assigned to either a HIIT group (12-week exercise HIIT intervention, 3 sessions/week), the HIIT + PA group (12-week exercise HIIT intervention, 3 sessions/week, plus 10,000 steps/day), or a control group (usual care).
Who Took Part
According to the abstract, 77 women were involved.
PubMed tags the participants as women only.
How the Study Was Run
The design is described as randomized and parallel-group.
The women were allocated by chance, so the IGF-1 LR3 group and the comparison group should start out alike.
Groups ran in parallel: each of the women stayed in one arm throughout.
What Was Measured
The primary outcome measure will the chronic change in IGF-1 concentration levels measured in saliva.
Secondary outcome measures will be: (i) executive functions; (ii) body composition; (iii) physical fitness; (iv) physical activity; and (v) quality of life.
PubMed files the paper under topics including Executive Function, High-Intensity Interval Training, Insulin-Like Growth Factor I, Universities, Quality of Life, Physical Fitness and Brain.
The authors tagged it with the keywords HIIT, executive functions, female, insulin growth factor-1, sedentary lifestyle and young adult.
What This Means in Plain Language
The paper is a randomized and parallel-group study of IGF-1 LR3 in 77 women.
The publication is from 2023 (International journal of environmental research and public health), a journal based in Switzerland.
More context: the IGF-1 LR3 compound page, all human trials.
Our Notes on the Compound
IGF-1 LR3: A modified IGF-1 analog that escapes binding proteins, so it stays active ≥24 h.
Related Pages
Source: PubMed record. This explanation is written by PeptideWhiz from the public record. For research and education only. Not medical advice; no dosing information is given.